Gilead Swings to Profit on Reduced R&D Impairments

TL;DR

**Gilead's massive profit swing is a relief, but investors need to see sustained growth beyond cost cuts to truly get bullish.**

AI Summary

Gilead Sciences, Inc. reported a significant turnaround in its financial performance for the nine months ended September 30, 2025, achieving a net income of $6.327 billion compared to a net loss of $1.303 billion in the prior year period. This improvement was driven by a substantial reduction in acquired in-process research and development (IPR&D) expenses, which decreased from $4.674 billion in 2024 to $485 million in 2025, and a sharp decline in IPR&D impairments from $4.180 billion to $190 million. Total revenues increased slightly to $21.518 billion from $21.185 billion, primarily due to a rise in royalty, contract, and other revenues from $111 million to $505 million, including a $400 million recognition of previously constrained revenues from intellectual property sales. Product sales remained relatively flat at $21.013 billion. HIV product sales, led by Biktarvy, grew to $14.952 billion from $14.160 billion, while Veklury sales significantly declined from $1.461 billion to $700 million. The company's cash and cash equivalents decreased from $9.991 billion at December 31, 2024, to $7.330 billion at September 30, 2025, largely due to $6.482 billion in net cash used in financing activities, including $3.009 billion in dividend payments and $1.692 billion in common stock repurchases.

Why It Matters

Gilead's return to profitability, driven by lower R&D impairments and strategic revenue recognition, signals a more stable financial outlook for investors. The strong performance of HIV drugs like Biktarvy underscores the company's core strength, while the decline in Veklury sales highlights the evolving COVID-19 treatment market. This shift could impact future R&D focus and competitive positioning against rivals in oncology and virology. Employees may see increased job security and potential for growth as the company stabilizes, while customers could benefit from continued investment in key therapeutic areas. The broader market will watch if Gilead can sustain this profitability through pipeline advancements rather than just cost reductions.

Risk Assessment

Risk Level: medium — While Gilead reported a significant net income, the substantial reduction in IPR&D impairments from $4.180 billion in 2024 to $190 million in 2025 was a primary driver of profitability, rather than robust product sales growth. Product sales remained nearly flat at $21.013 billion, and cash and cash equivalents decreased by $2.661 billion, indicating ongoing cash outflows from financing activities like $3.009 billion in dividends and $1.692 billion in share repurchases.

Analyst Insight

Investors should closely monitor Gilead's upcoming pipeline developments and future product sales growth, particularly in oncology, to assess the sustainability of its profitability. While the current report shows a positive financial turnaround, the reliance on reduced impairments rather than organic revenue growth suggests a cautious approach is warranted before increasing exposure.

Financial Highlights

debt To Equity

1.04

revenue

$21.518B

operating Margin

37.4%

total Assets

$58.533B

total Debt

$24.941B

net Income

$6.327B

eps

N/A

gross Margin

78.0%

cash Position

$7.330B

revenue Growth

+1.6%

Revenue Breakdown

Key Numbers

• $6.327B — Net Income (Swung from a $1.303B net loss in the prior year, a significant financial turnaround.)
• $485M — Acquired IPR&D Expenses (Decreased substantially from $4.674B in 2024, a key driver of profitability.)
• $190M — IPR&D Impairments (Fell sharply from $4.180B in 2024, contributing to the net income improvement.)
• $21.518B — Total Revenues (Increased slightly from $21.185B, driven by royalty and contract revenues.)
• $14.952B — Total HIV Product Sales (Grew from $14.160B, demonstrating strength in core HIV franchise.)
• $700M — Veklury Sales (Decreased significantly from $1.461B, reflecting reduced demand for COVID-19 treatment.)
• $7.330B — Cash and Cash Equivalents (Decreased from $9.991B at year-end 2024, impacted by financing activities.)
• $3.009B — Dividends Paid (Significant cash outflow for shareholder returns during the nine-month period.)
• $1.692B — Common Stock Repurchases (Cash used for share buybacks, contributing to the decrease in cash.)
• $400M — Previously Constrained Revenues (Recognized from intellectual property sales, boosting royalty and other revenues.)

Key Players & Entities

• GILEAD SCIENCES, INC. (company) — Registrant in 10-Q filing
• Biktarvy (company) — Leading HIV product with $3.686 billion in Q3 2025 sales
• Veklury (company) — COVID-19 treatment with declining sales from $1.461 billion to $700 million
• Janssen Sciences Ireland Unlimited Company (company) — Partner for Symtuza revenue share
• Asegua Therapeutics LLC (company) — Gilead's subsidiary selling authorized generic versions of Epclusa and Harvoni
• $6.327 billion (dollar_amount) — Net income attributable to Gilead for nine months ended September 30, 2025
• $1.303 billion (dollar_amount) — Net loss attributable to Gilead for nine months ended September 30, 2024
• $4.674 billion (dollar_amount) — Acquired in-process R&D expenses for nine months ended September 30, 2024
• $485 million (dollar_amount) — Acquired in-process R&D expenses for nine months ended September 30, 2025
• $400 million (dollar_amount) — Previously constrained revenues recognized from intellectual property sales

FAQ

Risk Factors

• Acquired IPR&D Impairments [medium — financial]: The company experienced significant IPR&D impairments of $4.180 billion in the nine months ended September 30, 2024, which decreased to $190 million in the comparable 2025 period. While this reduction significantly boosted net income, large fluctuations in IPR&D impairments indicate potential volatility in the valuation of acquired research assets.
• Veklury Sales Decline [medium — market]: Veklury sales dropped from $1.461 billion to $700 million for the nine months ended September 30, 2025, a decrease of over 52%. This highlights the company's dependence on specific products and the market's sensitivity to evolving public health needs, such as the reduced demand for COVID-19 treatments.
• R&D Expense Management [medium — operational]: Acquired in-process research and development (IPR&D) expenses decreased from $4.674 billion to $485 million for the nine months ended September 30, 2025. While this improved profitability, the substantial decrease suggests a shift in acquisition strategy or a re-evaluation of R&D project values, which could impact future pipeline development.
• Cash Flow from Financing [medium — financial]: Net cash used in financing activities was $6.482 billion for the nine months ended September 30, 2025, including $3.009 billion in dividend payments and $1.692 billion in common stock repurchases. This significant outflow reduced cash and cash equivalents from $9.991 billion to $7.330 billion.
• Accrued Rebates [low — regulatory]: Accrued rebates increased from $3.892 billion at December 31, 2024, to $4.931 billion at September 30, 2025. This rise in liabilities related to drug pricing and government programs could indicate increasing pressure on gross margins or future cash outflows.

Industry Context

The biopharmaceutical industry continues to be driven by innovation in treating chronic diseases and emerging infectious threats. Companies like Gilead face intense competition, patent expirations, and evolving regulatory landscapes. The market for antiviral treatments, particularly for COVID-19, has seen significant shifts, impacting sales of established products.

Regulatory Implications

Gilead operates under stringent regulatory oversight from bodies like the FDA. Changes in healthcare policies, drug pricing regulations, and reimbursement practices can significantly impact revenue and profitability. The increase in accrued rebates suggests ongoing scrutiny and potential financial impact from these areas.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Glossary

Acquired in-process research and development expenses (IPR&D)

Costs incurred for research and development projects acquired from other companies that have not yet reached technological feasibility and have no alternative future use. (A significant factor in the reported net income turnaround, with a substantial decrease in expenses and impairments compared to the prior year.)

IPR&D Impairments

A write-down of the value of acquired in-process research and development assets when their carrying amount is deemed unrecoverable. (The sharp decline in IPR&D impairments from $4.180 billion to $190 million was a primary driver of the improved net income for the period.)

Veklury

Gilead's brand name for remdesivir, an antiviral medication used to treat COVID-19. (Sales of Veklury have significantly declined, indicating a shift in the market for COVID-19 treatments.)

Biktarvy

Gilead's combination HIV medication. (Continued growth in Biktarvy sales demonstrates the strength of Gilead's core HIV franchise.)

Royalty, contract and other revenues

Revenue generated from licensing agreements, collaborations, and sales of intellectual property. (This category saw a significant boost due to the recognition of previously constrained revenues from intellectual property sales.)

Common stock repurchases

The company buying back its own shares from the open market. (A significant use of cash ($1.692 billion) during the period, impacting the overall cash position.)

Year-Over-Year Comparison

Gilead Sciences has demonstrated a significant financial turnaround, swinging from a net loss of $1.303 billion to a net income of $6.327 billion for the nine months ended September 30, 2025. This improvement was largely driven by a substantial reduction in acquired IPR&D expenses and impairments, rather than organic revenue growth, which was only a modest 1.6% increase. While core HIV product sales grew, the significant decline in Veklury sales indicates market shifts. New risks related to the valuation of acquired R&D and the sustainability of revenue streams beyond core franchises may be emerging.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Select

Filing Documents

• gild-20250930.htm (10-Q) — 2459KB
• gildq32025ex1037severancep.htm (EX-10.37) — 251KB
• gildq32025ex311ceocertific.htm (EX-31.1) — 8KB
• gildq32025ex312cfocertific.htm (EX-31.2) — 7KB
• gildq32025ex32section906ce.htm (EX-32) — 6KB
• 0000882095-25-000047.txt ( ) — 11693KB
• gild-20250930.xsd (EX-101.SCH) — 61KB
• gild-20250930_cal.xml (EX-101.CAL) — 102KB
• gild-20250930_def.xml (EX-101.DEF) — 298KB
• gild-20250930_lab.xml (EX-101.LAB) — 733KB
• gild-20250930_pre.xml (EX-101.PRE) — 515KB
• gild-20250930_htm.xml (XML) — 2337KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 39 Item 4.

Controls and Procedures

Controls and Procedures 39 PART II. OTHER INFORMATION 41 Item 1.

Legal Proceedings

Legal Proceedings 41 Item 1A.

Risk Factors

Risk Factors 41 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 55 Item 3. Defaults Upon Senior Securities 55 Item 4. Mine Safety Disclosures 55 Item 5. Other Information 55 Item 6. Exhibits 55

SIGNATURES

SIGNATURES 60 We own or have rights to various trademarks, copyrights and trade names used in our business, including the following: GILEAD , GILEAD SCIENCES , KITE , AMBISOME , ATRIPLA , BIKTARVY , CAYSTON , COMPLERA , DESCOVY , DESCOVY FOR PREP , EMTRIVA , EPCLUSA , EVIPLERA , GENVOYA , HARVONI , HEPCLUDEX , HEPSERA , JYSELECA , LETAIRIS , LIVDELZI /LYVDELZI / , ODEFSEY , SOVALDI , STRIBILD , SUNLENCA , TECARTUS , TRODELVY , TRUVADA , TRUVADA FOR PREP , TYBOST , VEKLURY , VEMLIDY , VIREAD , VOSEVI , YESCARTA , YEZTUGO /YEYTUO and ZYDELIG . Other trademarks and trade names are the property of their respective owners. Certain amounts and percentages in this Quarterly Report on Form 10-Q may not sum or recalculate due to rounding. This Quarterly Report on Form 10-Q, including Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations and Part II, Item 1A. Risk Factors, contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. Words such as "ambition," "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "goal," "hope," "intend," "may," "might," "outlook," "plan," "priority," "project," "seek," "should," "target" and variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, any statements other than statements of historical fact are forward-looking statements, including statements regarding overall trends; operating cost, product sales and revenue trends; liquidity and capital needs; plans and expectations with respect to products, product candidates, corporate strategy, business and operations, financial projections, strategic investments and the use of capital; expectations regarding the impact of the Inflation Reduction Act and the One Big Beautiful Bill Act, chan

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (in millions, except per share amounts) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 7,330 $ 9,991 Short-term marketable debt securities 19 — Accounts receivable, net 5,095 4,420 Inventories 1,785 1,710 Prepaid and other current assets 3,645 3,052 Total current assets 17,874 19,173 Property, plant and equipment, net 5,500 5,414 Long-term marketable debt securities 2,005 — Intangible assets, net 17,970 19,948 Goodwill 8,314 8,314 Deferred tax assets 1,998 2,378 Other long-term assets 4,873 3,769 Total assets $ 58,533 $ 58,995 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 808 $ 833 Accrued rebates 4,931 3,892 Current portion of long-term debt, net 2,806 1,815 Other current liabilities 3,752 5,464 Total current liabilities 12,298 12,004 Long-term debt, net 22,135 24,896 Long-term income taxes payable 866 830 Deferred tax liabilities 597 724 Other long-term liabilities 1,182 1,295 Commitments and contingencies (Note 10) Stockholders' equity: Preferred stock, par value $ 0.001 per share; 5 shares authorized; no ne outstanding — — Common stock, par value $ 0.001 per share; 5,600 shares authorized; 1,242 and 1,246 shares issued and outstanding, respectively 1 1 Additional paid-in capital 8,678 7,700 Accumulated other comprehensive income 36 132 Retained earnings 12,825 11,497 Total Gilead stockholders' equity 21,540 19,330 Noncontrolling interest ( 84 ) ( 84 ) Total stockholders' equity 21,456 19,246 Total liabilities and stockholders' equity $ 58,533 $ 58,995 See accompanying notes. 3 GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) Three Months Ended Nine Months Ended September 30, September 30, (in millions, except per share amounts) 2025 2024 2025 2024 Revenues: Product sales $ 7,345